Pharmetheus continues to monitor the challenges presented by the COVID-19 pandemic and its effects on our company and in the field of clinical drug development. Read more about our approach and latest updates here.

Pharmetheus is looking for a Quality Control - Medical Writer Consultant to support our team. Read more here here.

We are happy to have Quentin onboard in our Enabling team. Previously he was as a scientist at SGS Exprimo (2011-2020). His research experience includes model-based simulations for supporting drug development decision making, many of which have been submission projects. He has been extensively involved in the development of the Simulo software for clinical trial simulation. Quentin will work from his home office in Belgium. See his bio here.

We are happy to have Anaïs onboard as a MIDD consultant. Her research experience (from academic groups as well as pharmaceutical companies) includes PK/PD modeling, simulations and dosing individualization. Anaïs will work from our Uppsala office in Sweden. See her bio here.

We would like to bring everyone's attention to a recent publication highlighting the benefits of an innovative quantitative modeling framework. The framework uses circulating tumor cell counts as a predictor of overall survival in metastatic colorectal cancer. Dr. Ida Neldemo (previously Netterberg), main author of the publication, conducted this work before joining Pharmetheus, during her PhD under the supervision of Pharmetheus’ advisors Prof. Mats Karlsson and Prof. Lena Friberg. Find the article here.

Pharmetheus stands ready to apply the principles of this publication to our client’s drug development program.

We continue to expand our team with Medical Writers/Quality Control Reviewers. Ninni Sylenius has been working with clinical studies in the cardiovascular field at Uppsala Clinical Research Center, and previously with pharmacovigilance at Novartis and Sanofi Pasteur MSD. She also has experience as a research assistant in cognitive neuroscience and as a community pharmacist. Ninni is based in Stockholm, Sweden.

We continue to expand our team with Medical Writers/Quality Control Reviewers. Viviana has been working as a freelance medical writer and editor in several clinical fields. Her previous research experience includes database genotype analysis and in vitro work in the field of Immunology of liver transplantation. Viviana is based in Luleå, Sweden.

We expand our team with Medical Writers/Quality Control Reviewers. Mikael’s research experience includes bioinformatics and biostatistics, applied in autoimmune diseases and CNS disorders. He has previous experience in drug development and production at Roche and GE Healthcare. Mikael is based in Rennes, France. See Mikael's bio here.

Pharmetheus colleagues are co-authors to 4 abstracts to be presented at the virtual International Society on Thrombosis and Haemostasis Congress 12-14 July 2020.

Read more about our support to drug development of a recombinant von Willebrand factor in patients with severe von Willebrand disease (abstract numbers PB1541 and PB1544) and of dabigatran in children with venous thromboembolism (abstract numbers PB1271 and PB1272): https://www.isth2020.org/abstracts

Physiologically based pharmacokinetic (PBPK) modelling is a technique to predict drug concentration at the site of pharmacological action. It appears natural to combine PBPK models with quantitative systems pharmacology (QSP) models to get a mechanistic understanding of the PK/PD relationship(s) of the drug in patients.

PBPK-QSP models build on prior knowledge, including (patho-)physiology and pharmacology. The independent representations of drug and system parameters allow for extrapolation to scenarios beyond observation. The methodology can enhance drug development programs by informing biomarker strategies and early prediction of clinical outcome. Read more about PBPK-QSP here.

We would like to congratulate our advisor Andrew Hooker (see bio) on his new position as a Professor of Pharmacometrics at Uppsala University. Andrew was part of founding Pharmetheus in 2012 and regularly contributes valuable expert advice on topics such as optimization of study design and pharmacometrics methodology. Congratulations, Andy!

We are happy to welcome Henrik Hellerstedt in our growing IT team. Henrik has worked as a senior IT consultant and has experience as an IT manager in both public and large private entities. Henrik will be working as an IT system administrator and will be based in the Uppsala Office. Glad to have you onboard, Henrik!

We have now joined the COVID-19 Pharmacology Resource Center. Conquering COVID-19 with clinical pharmacology, innovation, and collaboration.

More information available at the Covid-19 Pharmacology Resource web page

Pharmetheus is currently working with a number of clients to address the impact of the current COVID-19 epidemic to their ongoing clinical drug development programs. We would like to share our high level approach with the community at large. We see the current situation as both a challenge to our industry/sector but also an opportunity for appropriate and quantitative approaches to mitigate upon these challenges. We believe there are "fit for purpose" options for a broad range of plausible scenarios in clinical trial conduct that have emerged or could emerge.

See our approach

We are very happy to welcome two new team members, Julie Janssen, MIDD consultant, and Anna Pousette, Contracts Manager. Julie's research experience includes the application of pharmacometrics in the clinical setting, chemotherapy and targeted therapies, as well as special patient populations (e.g. pediatrics and pregnancy). Julie is based in the Netherlands. See Julie's bio here. Anna has long experience of project coordination and procurement. Anna will work from our Uppsala office in Sweden. See Anna's bio here.

As active and enthusiastic members of the Open Systems Pharmacology (OSP) management team and provider of PBPK-QSP services, we would like to guide your attention to this recent publication, in CPT: Pharmacometrics & Systems Pharmacology, summarizing the principal ideas, organization and functionalities of the OSP platforms (PK-Sim/MoBi) and community.